The ocular drug delivery market in Asia Pacific is expected to grow toUS$ 5,608.56 million by 2028 from US$ 3,234.93 million in 2021. The market is estimated to grow at a CAGR of 8.2% from 2021 to 2028.
Several players operating in the ocular drug delivery market are developing and launching innovative products. The strategy of development and launch of new products helps companies to cater to a broad customer base. For instance, in June 2020, Senju Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced the launch of a new combination ophthalmic solution, AILAMIDE Combination Ophthalmic Suspension, for the treatment of glaucoma and ocular hypertension. Additionally, in May 2019, Menicon Co., Ltd launched Menicon Bloom Myopia Control Management System. Menicon Bloom Night therapy includes the overnight wearing of a specifically designed reverse geometry orthokeratology contact lens—manufactured in hyper oxygen-permeable Menicon Z rigid material that guarantees ideal corneal oxygenation for comfortable contact lens wear. Such developments and launches of new products are emerging as a key trend in the ocular drug delivery market.
The 2019 novel coronavirus (2019-nCoV), officially named COVID-19 by the WHO, has spread to more than 170 countries, including China prompting the WHO to declare the disease as a global pandemic. COVID-19 has had a tremendous impact on eye care delivery across the Asia Pacific region. In Bangladesh, all routine elective eye surgeries were postponed. Only emergency eye treatment was conducted only at outpatient departments. Moreover, patients were allowed to go to hospital only in the case of emergency. Similarly in India, outreach eye health services stopped largely thus impacting the rural communities. All elective surgeries were postponed. Non-cataract conditions like diabetic retinopathy and glaucoma patients affected due to break in follow-ups. Additionally, COVID-19 is having a tremendous impact on eye care in the Maldives. Due to the lock down people are not able to travel from one place to the other. Air and sea transport is at standstill and people from the outlying islands are not able to visit the nearest centre for eye care. A few centers in the capital Male are offering online consultations to patients. However, this has its limitations and healthcare professionals cannot do refractions online and a detailed anterior segment and posterior segment examinations is also not possible. Thus, COVID 19 is having a significant impact on the quality and quantity of eye care in the Maldives.
With the new features and technologies, companies can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the ocular drug delivery market. The Asia Pacific ocular drug delivery market is expected to grow at a good CAGR during the forecast period.
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Asia Pacific Ocular Drug Delivery Market Segmentation
Asia Pacific Ocular Drug Delivery Market – By Technology
- Implantable Ocular Drug Delivery Systems
- Particulate Drug Delivery Systems
- Nano-Particle Drug Delivery System
- Others
Asia Pacific Ocular Drug Delivery Market – By Formulation Type
- Solution
- Ointment
- Suspension
- Emulsion
- Liposomes and Nanoparticles
Asia Pacific Ocular Drug Delivery Market – By Disease type
- Cataract
- Dry Eye Syndrome
- Macular Degeneration
- Glaucoma
- Diabetic Retinopathy
- Diabetic Macular Edema
- Others
Asia Pacific Ocular Drug Delivery Market – By End User
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgical Centers
Asia Pacific Ocular Drug Delivery Market – By Country
- Japan
- China
- India
- South Korea
- Australia
- Rest of APAC
Asia Pacific Ocular Drug Delivery Market – Companies Mentioned
- AbbVie Inc.
- Bausch Health Companies Inc.
- Novartis AG
- Clearside Biomedical, Inc
- Taiwan Liposome Company, Ltd.
Asia Pacific Ocular Drug Delivery Report Scope
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 3,234.93 Million |
Market Size by 2028 | US$ 5,608.56 Million |
Global CAGR (2021 - 2028) | 8.2% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By Technology
|
Regions and Countries Covered | Asia-Pacific
|
Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset



Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
This text is related
to segments covered.

Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
This text is related
to country scope.
Trends and growth analysis reports related to Life Sciences : READ MORE..
- AbbVie Inc.
- Bausch Health Companies Inc.
- Novartis AG
- Clearside Biomedical, Inc.
- Taiwan Liposome Company, Ltd.